Log In Sign up
The largest database of trusted experimental protocols

Midostaurin pkc412

Manufactured by LC Laboratories
Visit Supplier
Sourced in United States

Midostaurin/PKC412 is a small molecule inhibitor of multiple protein kinases, including PKC, FLT3, PDGFR, and KIT. It is a white crystalline powder provided as a research chemical by LC Laboratories.

Automatically generated - may contain errors

Lab products found in correlation

Panobinostat lbh589, by Selleck Chemicals (1 mentions) Hdaci, by Selleck Chemicals (1 mentions) Trametinib gsk1120212, by Selleck Chemicals (1 mentions) Adavosertib mk 1775, by Selleck Chemicals (1 mentions) Wee1i, by Selleck Chemicals (1 mentions) Sotorasib amg 510, by MedChemExpress (1 mentions) Bix02189, by Bio-Techne (1 mentions) Afatinib, by LC Laboratories (1 mentions) Pimozide, by Merck Group (1 mentions) Piceatannol, by Merck Group (1 mentions) Erlotinib, by Chemietek (1 mentions) Dasatinib, by Chemietek (1 mentions) Sunitinib, by Chemietek (1 mentions) Vorinostat, by Chemietek (1 mentions) Everolimus, by Chemietek (1 mentions) Ponatinib, by Selleck Chemicals (1 mentions) Lapatinib, by Chemietek (1 mentions) Sorafenib, by Chemietek (1 mentions) Rad001, by Chemietek (1 mentions) Gefitinib, by Chemietek (1 mentions)

2 protocols using midostaurin pkc412

1

Pharmacological Inhibition of Oncogenic Signaling

Check if the same lab product or an alternative is used in the 5 most similar protocols
Pharmacological inhibitors to MEK1/2 (Trametinib/GSK1120212, MEKi), HDAC (Panobinostat/LBH589, HDACi) and WEE1 (Adavosertib/MK-1775, WEE1i) were acquired from Selleckchem; to MEK5-K2 (BIX02189, MEK5i) was purchased from Tocris. Lestaurtinib/L6307 (mtPKCi), Neratinib (pan-HERi) and Afatinib (EGFRi) were obtained from LC Laboratories, and Midostaurin/PKC412 (mtPKCi), Sotorasib/AMG-510 (KRASi), Darovasertib (PKCAi), Barasertib (AURKBi), Adagrasib/MRTX849 (KRASi) and MG132 (proteasome inhibitor) were purchased from MedChemExpress. Dabrafenib (RAFi) was a kind gift from Imanol Arozarena (Navarrabiomed, Spain).
Macaya I., Roman M., Welch C., Entrialgo-Cadierno R., Salmon M., Santos A., Feliu I., Kovalski J., Lopez I., Rodriguez-Remirez M., Palomino-Echeverria S., Lonfgren S.M., Ferrero M., Calabuig S., Ludwig I.A., Lara-Astiaso D., Jantus-Lewintre E., Guruceaga E., Narayanan S., Ponz-Sarvise M., Pineda-Lucena A., Lecanda F., Ruggero D., Khatri P., Santamaria E., Fernandez-Irigoyen J., Ferrer I., Paz-Ares L., Drosten M., Barbacid M., Gil-Bazo I, & Vicent S. (2023). Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer. Nature Communications, 14, 6332.
+ Open protocol
+ Expand
2

Targeted Drug Screening Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Bosutinib, masitinib and midostaurin (PKC412) were purchased from LC Laboratories (Woburn, MA, USA), ponatinib from Selleck Chemicals (Houston, TX, USA), piceatannol and pimozide from Sigma Aldrich (San Louis, MO, USA), and dasatinib, sorafenib, sunitinib, tozasertib, vorinostat, everolimus (RAD001), erlotinib, gefitinib, and lapatinib from ChemieTek (Indianapolis, IN, USA). Imatinib, nilotinib, and BEZ235 were kindly provided by Dr.E.Buchdunger and Dr.P.W.Manley (Novartis, Basel, Switzerland). Stock solutions of drugs were prepared by dissolving in DMSO (Merck, Darmstadt, Germany). A specification of targeted drugs is shown in Supplementary Table S1. RPMI 1640 medium and fetal calf serum (FCS) were from PAA Laboratories (Pasching, Austria), 3H-thymidine from Amersham (Buckinghamshire, United Kingdom), and the Annexin V-FITC Kit from eBiosciences (San Diego, CA, USA). Recombinant human (rh) stroma cell-derived factor-1 alpha (SDF-1α) and rh eotaxin were purchased from R&D Systems (Minneapolis, MN, USA), and rh interleukin-5 (IL-5) from BD Bioscience (San José, CA, USA). A specification of monoclonal antibodies (mAb) used in this study is shown in Supplementary Table S2.
Sadovnik I., Lierman E., Peter B., Herrmann H., Suppan V., Stefanzl G., Haas O., Lion T., Pickl W., Cools J., Vandenberghe P, & Valent P. (2014). Identification of Ponatinib as a potent inhibitor of growth, migration and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA. Experimental hematology, 42(4), 282-293.e4.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!